Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-vaccenic acid synthesis in diet-induced obese mice

Journal of Lipid Research

Volumn 54, Issue 1, 2013, Pages 71-84

  Tripathy, Sasmita ^a,b   Jump, Donald B ^a,b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Cis vaccenic acid rictor; Fatty acid elongase 5; Gluconeogenesis forkhead box O1; Mammalian target of rapamycin complex 2; Palmitoleic acid

Indexed keywords

ADENOVIRUS VECTOR; FATTY ACID ELONGASE 5; LINOLEIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MONOUNSATURATED FATTY ACID; PALMITOLEIC ACID; POLYUNSATURATED FATTY ACID; PROTEIN KINASE B; PROTEIN KINASE B BETA; REGULATOR PROTEIN; RICTOR PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; VACCENIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; FATTY ACID ANALYSIS; FATTY ACID SYNTHESIS; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LIPID COMPOSITION; LIVER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ACETYLTRANSFERASES; ANIMALS; CARRIER PROTEINS; DIET; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCKDOWN TECHNIQUES; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; HEP G2 CELLS; HUMANS; LIVER; MACROLIDES; MALE; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; OBESITY; OLEIC ACIDS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84871180269     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M028787     Document Type: Article

References (54)

1. Wang, Y., M. Torres-Gonzalez, S. Tripathy, D. Botolin, B. Christian, and D. B. Jump. 2008. Elevated hepatic fatty acid elongase-5 activity affects multiple pathways controlling hepatic lipid and carbohydrate composition. J. Lipid Res. 49: 1538-1552.
2. Tripathy, S., M. Torres-Gonzalez, and D. B. Jump. 2010. Elevated hepatic fatty acid elongase-5 activity corrects dietary fat-induced hyperglycemia in obese C57BL/6J mice. J. Lipid Res. 51: 2642-2654.
3. Moon, Y. A., R. E. Hammer, and J. D. Horton. 2009. Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. J. Lipid Res. 50: 412-423.
4. Wang, Y., D. Botolin, J. Xu, B. Christian, E. Mitchell, B. Jayaprakasam, M. G. Nair, J. M. Peters, J. V. Busik, L. K. Olson, et al. 2006. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J. Lipid Res. 47: 2028-2041. (Pubitemid 44401991)
5. Green, C. D., C. G. Ozguden-Akkoc, Y. Wang, D. B. Jump, and L. K. Olson. 2010. Role of fatty acid elongases in determination of de novo synthesized monounsaturated fatty acid species. J. Lipid Res. 51: 1871-1877.
6. Ohno, Y., S. Suto, M. Yamanaka, Y. Mizutani, S. Mitsutake, Y. Igarashi, T. Sassa, and A. Kihara. 2010. ELOVL1 production of C24 acyl-CoAs is linked to C24 sphingolipid synthesis. Proc. Natl. Acad. Sci. USA. 107: 18439-18444.
7. Aoki, M., H. Jiang, and P. K. Vogt. 2004. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc. Natl. Acad. Sci. USA. 101: 13613-13617. (Pubitemid 39238451)
8. Guo, S., G. Rena, S. Cichy, X. He, P. Cohen, and T. Unterman. 1999. Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J. Biol. Chem. 274: 17184-17192.
9. Matsumoto, M., A. Pocai, L. Rossetti, R. A. Depinho, and D. Accili. 2007. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab. 6: 208-216. (Pubitemid 47336849)
10. Puigserver, P., J. Rhee, J. Donovan, C. J. Walkey, J. C. Yoon, F. Oriente, Y. Kitamura, J. Altomonte, H. Dong, D. Accili, et al. 2003. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 423: 550-555. (Pubitemid 36648580)
11. Cho, H., J. Mu, J. K. Kim, J. L. Thorvaldsen, Q. Chu, E. B. Crenshaw III, K. H. Kaestner, M. S. Bartolomei, G. I. Shulman, and M. J. Birnbaum. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 292: 1728-1731. (Pubitemid 32506248)
12. Brozinick, J. T., Jr., and M. J. Birnbaum. 1998. Insulin, but not contraction, activates Akt/PKB in isolated rat skeletal muscle. J. Biol. Chem. 273: 14679-14682.
13. Kohn, A. D., S. A. Summers, M. J. Birnbaum, and R. A. Roth. 1996. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J. Biol. Chem. 271: 31372-31378. (Pubitemid 26408588)
14. Liao, J., A. Barthel, K. Nakatani, and R. A. Roth. 1998. Activation of protein kinase B/Akt is sufficient to repress the glucocorticoid and cAMP induction of phosphoenolpyruvate carboxykinase gene. J. Biol. Chem. 273: 27320-27324. (Pubitemid 28500447)
15. Cho, H., J. L. Thorvaldsen, Q. Chu, F. Feng, and M. J. Birnbaum. 2001. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276: 38349-38352.
16. Yang, J., P. Cron, V. Thompson, V. M. Good, D. Hess, B. A. Hemmings, and D. Barford. 2002. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell. 9: 1227-1240. (Pubitemid 34722302)
17. Dormond, O., J. C. Madsen, and D. M. Briscoe. 2007. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J. Biol. Chem. 282: 23679-23686. (Pubitemid 47311969)
18. Dong, L. Q., and F. Liu. 2005. PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am. J. Physiol. Endocrinol. Metab. 289: E187-E196. (Pubitemid 41076617)
19. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307: 1098-1101. (Pubitemid 40262113)
20. Zong, H., C. C. Bastie, J. Xu, R. Fassler, K. P. Campbell, I. J. Kurland, and J. E. Pessin. 2009. Insulin resistance in striated muscle-specific integrin receptor beta1-deficient mice. J. Biol. Chem. 284: 4679-4688.
21. Pearce, L. R., X. Huang, J. Boudeau, R. Pawlowski, S. Wullschleger, M. Deak, A. F. Ibrahim, R. Gourlay, M. A. Magnuson, and D. R. Alessi. 2007. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 405: 513-522. (Pubitemid 47172049)
22. Wullschleger, S., R. Loewith, and M. N. Hall. 2006. TOR signaling in growth and metabolism. Cell. 124: 471-484. (Pubitemid 43199434)
23. Hresko, R. C., and M. Mueckler. 2005. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280: 40406-40416. (Pubitemid 41780527)
24. Guertin, D. A., D. M. Stevens, C. C. Thoreen, A. A. Burds, N. Y. Kalaany, J. Moffat, M. Brown, K. J. Fitzgerald, and D. M. Sabatini. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell. 11: 859-871. (Pubitemid 44804279)
25. Wang, R. H., H. S. Kim, C. Xiao, X. Xu, O. Gavrilova, and C. X. Deng. 2011. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J. Clin. Invest. 121: 4477-4490.
26. Hagiwara, A., M. Cornu, N. Cybulski, P. Polak, C. Betz, F. Trapani, L. Terracciano, M. H. Heim, M. A. Ruegg, and M. N. Hall. 2012. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab. 15: 725-738.
27. Zhang, C., A. A. Wendel, M. R. Keogh, T. E. Harris, J. Chen, and R. A. Coleman. 2012. Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling. Proc. Natl. Acad. Sci. USA. 109: 1667-1672.
28. Housley, M. P., J. T. Rodgers, N. D. Udeshi, T. J. Kelly, J. Shabanowitz, D. F. Hunt, P. Puigserver, and G. W. Hart. 2008. O-GlcNAc regulates FoxO activation in response to glucose. J. Biol. Chem. 283: 16283-16292.
29. Qiang, L., A. S. Banks, and D. Accili. 2010. Uncoupling of acetylation from phosphorylation regulates FoxO1 function independent of its subcellular localization. J. Biol. Chem. 285: 27396-27401.
30. Jump, D. B., M. Torres-Gonzalez, and L. K. Olson. 2011. Soraphen A, an inhibitor of acetyl CoA carboxylase activity, interferes with fatty acid elongation. Biochem. Pharmacol. 81: 649-660.
31. Lindsley, C. W., Z. Zhao, W. H. Leister, R. G. Robinson, S. F. Barnett, D. Defeo-Jones, R. E. Jones, G. D. Hartman, J. R. Huff, H. E. Huber, et al. 2005. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15: 761-764. (Pubitemid 40143162)
32. Moore, S. F., R. W. Hunter, and I. Hers. 2011. mTORC2 protein-mediated protein kinase B (Akt) serine 473 phosphorylation is not required for Akt1 activity in human platelets. J. Biol. Chem. 286: 24553-24560.
33. Gu, Y., J. Lindner, A. Kumar, W. Yuan, and M. A. Magnuson. 2011. Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size. Diabetes. 60: 827-837.
34. Breuleux, M., M. Klopfenstein, C. Stephan, C. A. Doughty, L. Barys, S. M. Maira, D. Kwiatkowski, and H. A. Lane. 2009. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol. Cancer Ther. 8: 742-753.
35. Zoncu, R., A. Efeyan, and D. M. Sabatini. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12: 21-35.
36. Efeyan, A., and D. M. Sabatini. 2010. mTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol. 22: 169-176.
37. Emerling, B. M., and A. Akcakanat. 2011. Targeting PI3K/mTOR signaling in cancer. Cancer Res. 71: 7351-7359.
38. Chen, C. H., T. Shaikenov, T. R. Peterson, R. Aimbetov, A. K. Bissenbaev, S. W. Lee, J. Wu, H. K. Lin, and Dos D. Sarbassov. 2011. ER stress inhibits mTORC2 and Akt signaling through GSK-3β-mediated phosphorylation of rictor. Sci. Signal. 4: ra10. doi: 10.1126/scisignal.2001731.
39. Dibble, C. C., J. M. Asara, and B. D. Manning. 2009. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol. Cell. Biol. 29: 5657-5670.
40. Julien, L. A., A. Carriere, J. Moreau, and P. P. Roux. 2010. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell. Biol. 30: 908-921.
41. Treins, C., P. H. Warne, M. A. Magnuson, M. Pende, and J. Downward. 2010. Rictor is a novel target of p70 S6 kinase-1. Oncogene. 29: 1003-1016.
42. Depner, C. M., M. Torres-Gonzalez, S. Tripathy, G. Milne, and D. B. Jump. 2012. Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr-/- mice. J. Nutr. 142: 1495-1503.
43. Jump, D. B., D. Botolin, Y. Wang, J. Xu, O. Demeure, and B. Christian. 2008. Docosahexaenoic acid (DHA) and hepatic gene transcription. Chem. Phys. Lipids. 153: 3-13.
44. Jump, D. B. 2011. Fatty acid regulation of hepatic lipid metabolism. Curr. Opin. Clin. Nutr. Metab. Care. 14: 115-120.
45. Botolin, D., Y. Wang, B. Christian, and D. B. Jump. 2006. Docosahexaneoic acid (22:6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 26S proteasome-dependent pathways. J. Lipid Res. 47: 181-192. (Pubitemid 43107461)
46. Miyazaki, M., M. T. Flowers, H. Sampath, K. Chu, C. Otzelberger, X. Liu, and J. M. Ntambi. 2007. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab. 6: 484-496. (Pubitemid 350163054)
47. Matsuzaka, T., H. Shimano, N. Yahagi, T. Kato, A. Atsumi, T. Yamamoto, N. Inoue, M. Ishikawa, S. Okada, N. Ishigaki, et al. 2007. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat. Med. 13: 1193-1202. (Pubitemid 47530641)
48. Cao, H., K. Gerhold, J. R. Mayers, M. M. Wiest, S. M. Watkins, and G. S. Hotamisligil. 2008. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell. 134: 933-944.
49. Gong, J., H. Campos, S. McGarvey, Z. Wu, R. Goldberg, and A. Baylin. 2011. Adipose tissue palmitoleic acid and obesity in humans: does it behave as a lipokine? Am. J. Clin. Nutr. 93: 186-191.
50. Guo, X., H. Li, H. Xu, V. Halim, W. Zhang, H. Wang, K. T. Ong, S. L. Woo, R. L. Walzem, D. G. Mashek, et al. 2012. Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice. PLoS ONE. 7: e39286.
51. Djoussé, L., N. R. Matthan, A. H. Lichtenstein, and J. M. Gaziano. 2012. Red blood cell membrane concentration of cis-palmitoleic and cis-vaccenic acids and risk of coronary heart disease. Am. J. Cardiol. 110: 539-544.
52. Yang, Z. H., H. Miyahara, and A. Hatanaka. 2011. Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay mice with genetic type 2 diabetes. Lipids Health Dis. 10: 120.
53. Jump, D. B. 2008. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr. Opin. Lipidol. 19: 242-247. (Pubitemid 351653561)
54. Wu, J. H., R. N. Lemaitre, F. Imamura, I. B. King, X. Song, D. Spiegelman, D. S. Siscovick, and D. Mozaffarian. 2011. Fatty acids in the de novo lipogenesis pathway and risk of coronary heart disease: the Cardiovascular Health Study. Am. J. Clin. Nutr. 94: 431-438.